Dr Reddy’s to market 3 Amgen drugs in India

G Naga Sridhar Hyderabad | Updated on January 16, 2018


To address needs in areas of oncology, osteoporosis

Pharma major Dr Reddy’s Laboratories Ltd has expanded its collaboration with Amgen in India to market and distribute three of the latter’s medicines in the domestic market.

As part of the collaboration, Hyderabad-based Dr Reddy’s will commericalise Amgen’s XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in the therapeutic areas of oncology and osteoporosis.

``These medicines provide unique treatment options to physicians to address an unmet medical need in the area of oncology and osteoporosis,’’ M V Ramana, Executive Vice-President and Head of Emerging Markets and India Business, Dr Reddy’s Laboratories, said in a release issued here on Friday.

XGEVA is a RANK ligand (RANKL) inhibitor and is approved in India for the prevention of skeletal related events in patients with advanced malignancies involving the bone.

Vectibix is an epidermal growth factor receptor (EGFR) antagonist, approved in India for the treatment of adult patients with wild-type KRAS metastatic colorectal cancer (m-CRC) as a first line treatment as mono-therapy, following disease progression in wild type RAS m-CRC as first-line combination with FOLFOX and in second line in combination with FOLFIRI after prior treatment with fluoropyrimidine-based chemotherapy (excluding irinotecan).

Prolia is a RANK ligand (RANKL) inhibitor approved in India for the treatment of post-menopausal women with osteoporosis.

Dr Reddy’s scrip gained 0.59 per cent on the BSE on Friday and is trading at Rs 3,160.05.

Published on September 16, 2016

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor